What is the 13F Pro Quality Score for PHGE?

13F Pro ranks BiomX Inc. (PHGE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PHGE's current score at https://13fpro.ai/research/PHGE (free sign-up required for the full ranking).

Where does 13F Pro source PHGE data?

All BiomX Inc. fundamentals and ownership data come directly from SEC EDGAR. BiomX Inc. files with the SEC under CIK 1739174. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PHGE in?

BiomX Inc. (PHGE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PHGE research updated on 13F Pro?

PHGE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BiomX Inc.(PHGE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1739174 PHGE stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PHGE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BiomX Inc. (PHGE), a Healthcare sector company. PHGE is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), BiomX Inc. reports net income of $-19.1M, free cash flow of $-5.4M. Top institutional holders of PHGE by reported 13-F value include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Nantahala Capital Management,, Ikarian Capital,, based on the most recent SEC filings. PHGE trades on the NYSE exchange and files with the SEC under CIK 1739174. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PHGE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BiomX Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-19.1M

Free Cash Flow

Q1 2026

$-5.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-27.8% YoY

$-36.2MFY 2025

FY18 $-12.7MFY19 $-20.6MFY22 $-28.3MFY25 $-36.2M

Operating Income

-52.3% YoY

$-41.5MFY 2025

FY18 $-12.5MFY19 $-22.2MFY22 $-27.2MFY25 $-41.5M

EPS (Diluted)

+2235.8% YoY

$22.19FY 2025

FY18 —FY19 —FY22 $0.95FY25 $22.19

Total Assets

-87.3% YoY

$5.8MFY 2025

FY18 $71.0MFY19 $92.1MFY22 $45.5MFY25 $5.8M

Total Debt

—FY 2025

FY18 —FY19 $1.6MFY22 $20.0MFY25 —

Op. Cash Flow

+9.3% YoY

$-26.4MFY 2025

FY18 $-11.3MFY19 $-17.6MFY22 $-29.1MFY25 $-26.4M

Metric	FY 2025	FY 2022	FY 2019	FY 2018	FY 2017
Net Income	$-36.2M -27.8%	$-28.3M -37.7%	$-20.6M -61.7%	$-12.7M	—
Operating Income	$-41.5M -52.3%	$-27.2M -22.6%	$-22.2M -77.7%	$-12.5M	—
EPS (Diluted)	$22.19 +2235.8%	$0.95	—	—	—
Total Assets	$5.8M -87.3%	$45.5M -50.6%	$92.1M +29.8%	$71.0M	—
Total Debt	—	$20.0M +1143.4%	$1.6M	—	—
Operating Cash Flow	$-26.4M +9.3%	$-29.1M -65.5%	$-17.6M -55.5%	$-11.3M	—

AI Insight: PHGE Financial Trends

BiomX swung to persistent operating losses and negative equity by Q1 2026, with cash burn accelerating despite narrowing operating margin in latest quarter.

• Operating income contracted from $-10M (Q2 2024) to $-18M (Q4 2025), then improved to $-1M (Q1 2026)—first near-breakeven quarter.

• Operating cash flow deteriorated from $-11M (Q2 2024) to $-4M (Q4 2025), but worsened to $-5M (Q1 2026).

• Equity eroded from $27M (Q2 2024) to negative $1M (Q3 2025 onward), signaling cumulative losses exceed net assets.

⚠ Net losses widened to $-19M in Q1 2026, the worst quarter on record; cash burn trajectory unsustainable without capital infusion.

⚠ Revenue figures absent across entire dataset—inability to assess top-line momentum or unit economics limits visibility.

AI Insight: PHGE Ratio Trends

BiomX profitability metrics are severely limited; only sparse ROE/ROA/ROIC data available, with Q1–Q2 2025 showing deep losses.

• ROE and ROA collapsed in Q1 2025 (−125.0% and −67.1%) and remained negative in Q2 2025 (−126.0% and −63.5%).

• Debt-to-equity ratio deteriorated from 0.30 in Q3 2024 to 0.46 in Q4 2024; leverage data absent since Q1 2025.

⚠ OpMargin, NPM, and ROIC data unavailable across all periods; limits ability to assess operational efficiency and capital returns.

⚠ No financial data reported for Q3 2025, Q4 2025, or Q1 2026 TTM; unclear if company ceased reporting or faces disclosure gaps.

Get alerted when PHGE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BiomX Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PHGE

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$492.8K131,272 sh
Nantahala Capital Management, LLC
$430.9K114,795 sh
Ikarian Capital, LLC
$73.1K19,473 sh
MORGAN STANLEY
$71.7K19,100 sh
JANE STREET GROUP, LLC
$44.4K11,829 sh
BARCLAYS PLC
$4.9K1,316 sh
UBS Group AG
$2.2K573 sh
ROYAL BANK OF CANADA
$1.0K251 sh
OSAIC HOLDINGS, INC.
$750.00200 sh
SBI Securities Co., Ltd.
$75.0020 sh

Fund	Value	Shares
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$492.8K	131,272
Nantahala Capital Management, LLC	$430.9K	114,795
Ikarian Capital, LLC	$73.1K	19,473
MORGAN STANLEY	$71.7K	19,100
JANE STREET GROUP, LLC	$44.4K	11,829
BARCLAYS PLC	$4.9K	1,316
UBS Group AG	$2.2K	573
ROYAL BANK OF CANADA	$1.0K	251
OSAIC HOLDINGS, INC.	$750.00	200
SBI Securities Co., Ltd.	$75.00	20

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PHGE on your watchlist

Track score changes the day BiomX Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PHGE a good stock to buy?

13F Pro's AI-powered analysis of BiomX Inc. (PHGE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PHGE are available on the PHGE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PHGE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PHGE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BiomX Inc.'s investment landscape.